Navigation Links
Champions Oncology Clarifies Misstatements in News Article
Date:7/18/2011

BALTIMORE, July 18, 2011 /PRNewswire/ -- Champions Oncology, Inc., formerly Champions Biotechnology, Inc. (OTC: CSBR) released the following statement to correct errors which recently appeared in Hebrew in the Israeli biotechnology business press and which came to the Company's attention on July 16, 2011:

"Recently, a Hebrew language business news service reported that Champions has agreed to create a subsidiary which will be used by Champions for the development of a drug compound that we have in-licensed.  Contrary to this news report, the Company has not made any final determination with respect to the future development of this drug compound."

As the Company stated in our Annual Report on Form 10-K for our fiscal year ended April 30, 2011 (filed on July 15, 2011):

Historically, our strategy was to use our technology platform to identify promising compounds that could be in-licensed during the preclinical phase.  The strategy was to invest in the clinical development of these compounds and then seek a partner that would bring them to market in exchange for some combination of upfront payments, milestone payments and royalties on sales.  Since 2007, the company pursued this strategy with four compounds.  All four of these compounds were subjected to Tumorgraft testing, and the results of one of the compounds warranted further investment.  During 2011, we changed our strategy and no longer intend to in-license additional compounds.  We have refocused the Company on developing advanced technologies to personalize the development and use of oncology drugs.  We intend to continue the development of the compound which warranted further investment and we are seeking a partner to finance the future development of the product.

We are working to assess potential financing alternatives for developing this compound, including the appropriate structure and valuation.  We do not yet have the information nee
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Champions Oncology Reports Full Year 2011 Financial Results
2. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
3. Champions Biotechnology Changes Name to Champions Oncology
4. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
5. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
6. Champions Biotechnology Reports Additions to its Management Team
7. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
9. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Earlier this year, the ... of hair regrowth in adult men and women with ... Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification of ... by products that over-promise and under-deliver, FDA Clearance underscores ... and confidence among more than 80 million men and ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The consumption ... back of the recession and high prices in 2008. ... has recovered and keeps on gaining momentum now. , ... stands at more than 100,000 thousand tonnes. No considerable ... Meantime, the global capacity rocketed during 2012-2013, registering 11% ...
(Date:3/27/2015)... YORK , 27. März 2015 /PRNewswire/ ... Prize in Biomedical Science für seine bahnbrechende ... Proteine zwischen Zellkompartimenten transportiert werden, sowie für ... Zellen zur Reaktion auf Stress nutzen, der ... Dr. Walter ist Professor für Biochemie an ...
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
Breaking Biology Technology:Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Neogen CEO adopts 10b5-1 Trading Plan 2
... in secret. , Most people did not know that ... Sandia National Laboratories was contributing important information to the ... that cause the disease anthrax. The spores were mailed ... offices and to two U.S. senators. Five people were ...
... Standards and Technology (NIST) have developed a radical new method ... small as one nanometer (one billionth of a meter).* Because ... a wide range of ions tailored to the task at ... for carving smaller features on semiconductors than now are possible ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Healthcare Conference on Tuesday, November 18,2008 at approximately 3:10 ... live and may be accessed through a link on ... The webcast,will be available for 30 days following the ...
Cached Biology Technology:FBI unveils science of anthrax investigation 2FBI unveils science of anthrax investigation 3Cold atoms could replace hot gallium in focused ion beams 2Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference 2
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... between Kent State University, Summa Health System and IC-MedTech Inc. ... promise of new drugs which may more effectively manage cancer ... 1.5 million new cases of cancer will be diagnosed this ... establish a goal of eliminating suffering and death due to ...
... of the worlds leading STM publishers, has signed publishing ... past half year. With this move, Springer will ... society journals and confirms its long tradition of dedication ... Asia. Agreements to start publishing their journals in ...
... Scientists know that inside each cell, a little engine ... instructions from genes in the nucleus that get carried to ... our daily needs. Now researchers at the University of Michigan ... scans the cells DNA for damage. When certain types of ...
Cached Biology News:Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 3Enzyme alerts cell's powerful army to repair DNA damage 2Enzyme alerts cell's powerful army to repair DNA damage 3
... Serum is obtained from ... from healthy, fasted donors. The ... any way and are maintained ... Total Protein Concentration : ...
Hamster serum...
... 96-well Filter Plates are offered in several ... um depth filter plates are ideal to ... Filtration is simple, versatile, and necessary to ... Captiva 10 um glass fiber and 20 ...
... Kit with CyScribe GFX Purification Kit, ... purification of Cy3- and Cy5-labeled cDNA.Optimized ... cDNA labeling and purification.Flexible and optimized ... labeling reactions with either Cy3- or ...
Biology Products: